Population Pharmacokinetic of Linezolid in Patients with Liver Dysfunction and Dosage Regimen Optimization

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022118

Enrollment

Unknown

Registered

2019-03-26

Start date

2019-04-10

Completion date

Unknown

Last updated

2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver dysfunction

Interventions

Case Series:linezolid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Aged = 18 years; (2) Patients with liver dysfunction, including advanced decompensated cirrhosis, severe hepatitis (liver failure), liver transplant patients, etc.; (3) G+ bacterial infection (confirmed or suspected by clinical evaluation); (4) Linezolid treatment (independent of clinical evaluation of the study). (5) Severe infection (confirmed or suspected by clinical evaluation); (6) In the same period, patients taking anti-G-bacteria infection or other anti-fungal drugs may also be included in the study.

Exclusion criteria

Exclusion criteria: (1) Patients who are scheduled to be hospitalized for <3 days; (2) Patients who are allergic to linezolid or who simultaneously use rifampicin to significantly affect the pharmacokinetics of linezolid in vivo; (3) Patients with poor compliance.

Design outcomes

Primary

Measure	Time frame
plasma concentration;plasma;	—

Countries

China

Contacts

Public ContactZhang Bikui

Institute of Clinical Pharmacy, Central South University

bikui-zh@126.com+86 13973116871

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026